Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Accumulated Expenses (2018 - 2021)

Historic Accumulated Expenses for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q3 2021 value amounting to $21.5 million.

  • Black Diamond Therapeutics' Accumulated Expenses rose 16161.33% to $21.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $21.5 million, marking a year-over-year increase of 16161.33%. This contributed to the annual value of $11.7 million for FY2020, which is 30289.76% up from last year.
  • According to the latest figures from Q3 2021, Black Diamond Therapeutics' Accumulated Expenses is $21.5 million, which was up 16161.33% from $18.5 million recorded in Q2 2021.
  • In the past 5 years, Black Diamond Therapeutics' Accumulated Expenses ranged from a high of $21.5 million in Q3 2021 and a low of $452000.0 during Q4 2018
  • Its 4-year average for Accumulated Expenses is $9.5 million, with a median of $8.2 million in 2020.
  • Per our database at Business Quant, Black Diamond Therapeutics' Accumulated Expenses surged by 54137.17% in 2019 and then surged by 16161.33% in 2021.
  • Quarter analysis of 4 years shows Black Diamond Therapeutics' Accumulated Expenses stood at $452000.0 in 2018, then surged by 541.37% to $2.9 million in 2019, then surged by 302.9% to $11.7 million in 2020, then surged by 84.09% to $21.5 million in 2021.
  • Its Accumulated Expenses was $21.5 million in Q3 2021, compared to $18.5 million in Q2 2021 and $14.1 million in Q1 2021.